<DOC>
	<DOCNO>NCT01207635</DOCNO>
	<brief_summary>The goal study evaluate antiproliferative effect Arimidex ductal lavage fluid Breast Cancer patient . Breast cancer lead cause cancer incidence second leading cause cancer mortality woman . Breast duct fluid provide biomarkers aid risk assessment develop breast cancer .</brief_summary>
	<brief_title>Evaluation Antiproliferative Effects Arimidex Ductal Lavage Fluid Patients With Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<criteria>Patient must history breast cancer . Patient must schedule receive standard treatment Arimidex adjuvant hormonal management . Patient must willing undergo duct lavage . Patient must sign Informed Consent .</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Arimidex</keyword>
</DOC>